Profile data is unavailable for this security.
About the company
Exscientia PLC is a drug design and development company. The Company combines precision design with integrated experimentation to invent and develop drugs. It uses artificial intelligence (AI) in drug discovery to progress AI-designed small molecules into a clinical setting. It uses the patient's tissue data to define optimal profiles for research, improve experimental assessment during design and improve outcomes in a medical setting. It has developed an internal pipeline focused on oncology, while its partnered pipeline extends to various other therapeutic areas. It combines genetic data and global literature in machine learning models to anticipate and confirm disease-target associations. The Company's experimental platform records responses in real patient samples allowing it to generate high-precision views of potential patient response. Its product pipeline consists of GTAEXS617, EXS4318, EXS74539, and EXS73565.
- Revenue in USD (TTM)27.16m
- Net income in USD-167.45m
- Incorporated2021
- Employees483.00
- LocationExscientia PLCThe Schrodinger BuildingOxford Science ParkOXFORD OX4 4GEUnited KingdomGBR
- Phone+44 186 581 8941
- Websitehttps://www.exscientia.ai/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astria Therapeutics Inc | 0.00 | -93.24m | 666.95m | 59.00 | -- | 2.58 | -- | -- | -2.30 | -2.30 | 0.00 | 6.32 | 0.00 | -- | -- | 0.00 | -32.43 | -64.48 | -33.78 | -68.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.62 | -- | -- | -- |
| Sana Biotechnology Inc | 0.00 | -244.90m | 668.51m | 328.00 | -- | 1.97 | -- | -- | -1.15 | -1.15 | 0.00 | 1.53 | 0.00 | -- | -- | 0.00 | -36.94 | -38.99 | -42.11 | -42.70 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.11 | -- | 112.71 | -- |
| Y-mAbs Therapeutics Inc | 86.55m | -24.61m | 689.94m | 100.00 | -- | 7.24 | -- | 7.97 | -0.5618 | -0.5618 | 1.98 | 2.14 | 0.6262 | 1.42 | 4.19 | 865,460.00 | -17.81 | -44.23 | -23.58 | -50.45 | 88.74 | -- | -28.44 | -181.13 | 2.72 | -- | 0.00 | -- | 29.96 | -- | 77.58 | -- | -- | -- |
| Mineralys Therapeutics Inc | 0.00 | -119.67m | 698.16m | 28.00 | -- | 2.41 | -- | -- | -2.71 | -2.71 | 0.00 | 5.84 | 0.00 | -- | -- | 0.00 | -39.26 | -- | -41.62 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -141.28 | -- | -- | -- |
| Exscientia PLC (ADR) | 27.16m | -167.45m | 703.15m | 483.00 | -- | 1.81 | -- | 25.89 | -1.31 | -1.31 | 0.2137 | 3.01 | 0.042 | -- | 26.88 | 56,234.72 | -25.87 | -- | -29.52 | -- | -32.45 | -- | -616.50 | -- | -- | -- | 0.0674 | -- | -26.24 | -- | -22.94 | -- | -- | -- |
| Olema Pharmaceuticals Inc | 0.00 | -109.63m | 710.10m | 80.00 | -- | 3.13 | -- | -- | -2.06 | -2.06 | 0.00 | 3.97 | 0.00 | -- | -- | 0.00 | -50.73 | -30.06 | -56.10 | -31.40 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.76 | -- | -- | -- |
| Arbutus Biopharma Corp | 6.74m | -76.70m | 710.59m | 73.00 | -- | 6.65 | -- | 105.40 | -0.4259 | -0.4259 | 0.0374 | 0.5643 | 0.0451 | -- | 3.57 | 92,356.16 | -51.29 | -52.62 | -59.50 | -58.11 | -- | -- | -1,137.65 | -537.81 | -- | -- | 0.00 | -- | -53.51 | 25.00 | -4.89 | -- | -2.40 | -- |
| Humacyte Inc | 0.00 | -139.66m | 722.67m | 183.00 | -- | -- | -- | -- | -1.26 | -1.26 | 0.00 | -0.237 | 0.00 | -- | -- | 0.00 | -91.17 | -- | -100.75 | -- | -- | -- | -- | -- | -- | -40.08 | -- | -- | -100.00 | -- | -825.83 | -- | -- | -- |
| ORIC Pharmaceuticals Inc | 0.00 | -110.78m | 723.77m | 107.00 | -- | 2.30 | -- | -- | -1.76 | -1.76 | 0.00 | 4.47 | 0.00 | -- | -- | 0.00 | -35.69 | -33.92 | -37.77 | -35.77 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.99 | -- | 10.09 | -- |
| MBX Biosciences Inc | 0.00 | -47.20m | 729.77m | 36.00 | -- | -- | -- | -- | -1.48 | -1.48 | 0.00 | 1.71 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.60 | -- | -- | -- |
| Stoke Therapeutics Inc | 16.74m | -105.46m | 735.18m | 110.00 | -- | 3.17 | -- | 43.91 | -2.10 | -2.10 | 0.3294 | 4.38 | 0.0628 | -- | 42.55 | 152,209.10 | -39.56 | -31.62 | -46.04 | -33.92 | -- | -- | -629.86 | -1,775.50 | -- | -- | 0.00 | -- | -29.22 | -- | -3.59 | -- | 11.56 | -- |
| Tourmaline Bio Inc | 0.00 | -35.69m | 737.45m | 44.00 | -- | 2.18 | -- | -- | -2.54 | -2.54 | 0.00 | 13.19 | 0.00 | -- | -- | 0.00 | -14.16 | -- | -14.64 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.99 | -- | -- | -- |
| Entrada Therapeutics Inc | 215.23m | 54.95m | 741.66m | 177.00 | 12.44 | 1.75 | 12.68 | 3.45 | 1.59 | 1.59 | 5.97 | 11.30 | 0.4141 | -- | 56.43 | 1,353,660.00 | 10.57 | -- | 13.68 | -- | -- | -- | 25.53 | -- | -- | -- | 0.00 | -- | -- | -- | 92.93 | -- | -- | -- |
Data as of Nov 08 2024. Currency figures normalised to Exscientia PLC's reporting currency: US Dollar USD
13.99%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Laurion Capital Management LPas of 30 Jun 2024 | 5.14m | 3.98% |
| Baillie Gifford & Co.as of 30 Sep 2024 | 3.85m | 2.98% |
| First Trust Advisors LPas of 30 Jun 2024 | 1.73m | 1.34% |
| Bill & Melinda Gates Foundation Trust (Investment Management)as of 30 Jun 2024 | 1.59m | 1.23% |
| MIC Capital Management UK LLPas of 30 Jun 2024 | 1.54m | 1.19% |
| Platinum Investment Management Ltd.as of 30 Sep 2024 | 1.46m | 1.13% |
| Woodline Partners LPas of 30 Jun 2024 | 1.14m | 0.88% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 755.77k | 0.59% |
| Wells Fargo Clearing Services LLCas of 30 Jun 2024 | 487.91k | 0.38% |
| Mellon Investments Corp.as of 30 Jun 2024 | 388.46k | 0.30% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
